269 related articles for article (PubMed ID: 34698261)
1. Therapeutic Significance of microRNA-Mediated Regulation of PARP-1 in SARS-CoV-2 Infection.
Dash S; Dash C; Pandhare J
Noncoding RNA; 2021 Sep; 7(4):. PubMed ID: 34698261
[TBL] [Abstract][Full Text] [Related]
2. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
3. Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis.
Rajawat J; Chandra A
Curr Drug Targets; 2021; 22(13):1477-1484. PubMed ID: 33494667
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Host miRNA-223-3p to SARS-CoV-Induced Lung Inflammatory Pathology.
Morales L; Oliveros JC; Enjuanes L; Sola I
mBio; 2022 Apr; 13(2):e0313521. PubMed ID: 35229638
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Heer CD; Sanderson DJ; Voth LS; Alhammad YMO; Schmidt MS; Trammell SAJ; Perlman S; Cohen MS; Fehr AR; Brenner C
J Biol Chem; 2020 Dec; 295(52):17986-17996. PubMed ID: 33051211
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-Mediated Regulation of the Virus Cycle and Pathogenesis in the SARS-CoV-2 Disease.
Battaglia R; Alonzo R; Pennisi C; Caponnetto A; Ferrara C; Stella M; Barbagallo C; Barbagallo D; Ragusa M; Purrello M; Di Pietro C
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947989
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.
Panda M; Kalita E; Singh S; Kumar K; Rao A; Prajapati VK
Life Sci; 2022 Sep; 305():120761. PubMed ID: 35787998
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
Mohan SV; Hemalatha M; Kopperi H; Ranjith I; Kumar AK
Chem Eng J; 2021 Feb; 405():126893. PubMed ID: 32901196
[TBL] [Abstract][Full Text] [Related]
10. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
11. The MicroRNA Days: The COVID-19 Pandemic from the Point of View of Short RNAs.
Izzotti A
Microrna; 2021; 10(4):226-228. PubMed ID: 34963439
[TBL] [Abstract][Full Text] [Related]
12. miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery.
Alam T; Lipovich L
Noncoding RNA; 2021 Mar; 7(1):. PubMed ID: 33801496
[TBL] [Abstract][Full Text] [Related]
13. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
14. Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors.
Rampogu S; Jung TS; Ha MW; Lee KW
Sci Rep; 2023 Jun; 13(1):10583. PubMed ID: 37386052
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Activation of PARP as a SARS-CoV-2 Therapeutic Target-Is It a Bait for the Virus or the Best Deal We Could Ever Make with the Virus? Is AMBICA the Potential Cure?
Puthanveetil P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830743
[TBL] [Abstract][Full Text] [Related]
16. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
[TBL] [Abstract][Full Text] [Related]
17. The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.
Kouhpayeh S; Shariati L; Boshtam M; Rahimmanesh I; Mirian M; Esmaeili Y; Najaflu M; Khanahmad N; Zeinalian M; Trovato M; Tay FR; Khanahmad H; Makvandi P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064039
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
Hum C; Loiselle J; Ahmed N; Shaw TA; Toudic C; Pezacki JP
Drugs; 2021 Apr; 81(5):517-531. PubMed ID: 33638807
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
